

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
8 February 2001 (08.02.2001)

PCT

(10) International Publication Number  
**WO 01/08687 A1**

- (51) International Patent Classification<sup>7</sup>: A61K 31/495, A61P 15/10, A61K 9/48
- (21) International Application Number: PCT/US00/11136
- (22) International Filing Date: 26 April 2000 (26.04.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/146,924 3 August 1999 (03.08.1999) US
- (71) Applicant (*for all designated States except US*): LILLY ICOS LLC [US/US]; 1209 Orange Street, Wilmington, DE 19801 (US).
- (72) Inventors; and  
(75) Inventors/Applicants (*for US only*): ANDERSON, Neil, R. [US/US]; 906 Northwestern Avenue, West Lafayette, IN 47906 (US). GULLAPALLI, Rampurna, P. [US/US]; 1921 New Garden Road, Apt. N-108, Greensboro, NC 27410 (US).
- (74) Agent: NAPOLI, James, J.; Marshall, O'Toole, Gerstein, Murray & Borun, 6300 Sears Tower, 233 South Wacker Drive, Chicago, IL 60606 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— With international search report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 01/08687 A1

(54) Title: BETA-CARBOLINE PHARMACEUTICAL COMPOSITIONS

(57) Abstract: A soft capsule containing a solution or suspension of a PDE5 inhibitor, and use of the capsule in treating sexual dysfunction.

- 1 -

 **$\beta$ -CARBOLINE PHARMACEUTICAL COMPOSITIONS****CROSS REFERENCE TO RELATED APPLICATION**

5                   This application claims the benefit of  
provisional U.S. Patent Application Serial No.  
60/146,924, filed August 3, 1999.

**FIELD OF THE INVENTION**

10

                  This invention relates to the fields of  
pharmaceutical and organic chemistry involving  $\beta$ -  
carboline compounds that are useful in the treatment  
of various medical indications where inhibition of  
15                   type 5 cGMP-specific phosphodiesterase is desired.  
More particularly,  $\beta$ -carboline compounds are formu-  
lated in a manner providing uniform potency, and  
desirable stability and bioavailability character-  
istics.

20

**BACKGROUND OF THE INVENTION**

                  The biochemical, physiological, and clini-  
cal effects of cyclic guanosine 3',5'-monophosphate  
25                   specific phosphodiesterase (cGMP-specific PDE) in-  
hibitors suggest their utility in a variety of  
disease states in which modulation of smooth muscle,  
renal, hemostatic, inflammatory, and/or endocrine  
function is desired. Type 5 cGMP-specific phospho-  
30                   diesterase (PDE5) is the major cGMP hydrolyzing  
enzyme in vascular smooth muscle, and its expression  
in penile corpus cavernosum has been reported (A.  
Taher et al., J. Urol., 149, pp. 285A (1993)).

- 2 -

Thus, PDE5 is an attractive target in the treatment of sexual dysfunction (K.J. Murray, *DN&P* 6(3), pp. 150-56 (1993)).

5 Daugan U.S. Patent No. 5,859,006 discloses a class of  $\beta$ -carbolines, and pharmaceutical compositions thereof, which are useful in the treatment of conditions where inhibition of PDE5 is desired. Also, see PCT publication WO 97/03675 disclosing the use of such  $\beta$ -carbolines for the treatment of sexual  
10 dysfunction.

The poor solubility of many  $\beta$ -carbolines useful as PDE5 inhibitors has prompted the development of coprecipitate preparations, as disclosed in Butler U.S. Patent No. 5,985,326. Briefly de-  
15 scribed, coprecipitates of  $\beta$ -carbolines with a polymer, e.g., hydroxypropyl methylcellulose phthalate, were prepared, then milled, mixed with excipients, and compressed into tablets for oral administration. However, studies revealed some difficulties in generating precisely reproducible lots of coprecipitate  
20 product, thereby making the use of coprecipitates less than ideal for pharmaceutical formulations.

In addition, clinical studies involving administration of tablets containing such a coprecipitate preliminarily revealed that maximum blood  
25 concentration of the  $\beta$ -carboline is achieved in 3 to 4 hours, with the average time for onset of a therapeutic effect not yet precisely determined. When used for the treatment of sexual dysfunction, such as male erectile dysfunction or female arousal dis-  
30 order, a more rapid attainment of maximum blood concentration, along with a greater prospect for rapid onset of therapeutic effect, is desired by


- 3 -

patients, who prefer more immediate effects.

Accordingly, there is a continuing need in the art for oral dosage forms of  $\beta$ -carbolines, and pharmaceutical compositions thereof, useful in the treatment of conditions where inhibition of PDE5 is beneficial.

### SUMMARY OF THE INVENTION

This invention provides pharmaceutical formulations comprising a compound of structural formula (I):



(I)

named (6R-trans)-6-(1,3-benzodioxol-5-yl)-2,3,4,7,12,12a-hexahydro-2-methylpyrazino-[1',2':1,6]pyrido[3,4-b]indole-1,4-dione, and alternatively named (6R,12R)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido-3,4-b]indole-1,4-dione,

and pharmaceutically acceptable salts and solvates thereof, wherein the compound preferably is provided as a free drug either dissolved or suspended in a pharmaceutically acceptable solvent,

- 4 -

and the resulting solution or suspension is encapsulated in a soft capsule shell.

5 A preferred pharmaceutical composition comprises about 1% to about 45% by weight of the compound of structural formula (I), preferably provided as free drug, either dissolved or suspended in a pharmaceutically acceptable solvent. The composition is encapsulated in a soft shell, such as a gelatin shell, in a sufficient amount to provide 10 an oral dose of the compound of structural formula (I) of about 1 to about 20 mg, preferably about 2 to about 20 mg, more preferably about 5 to about 20 mg, and most preferably about 5 to about 15 mg. A particularly preferred soft capsule of the present invention contains a 5 mg or a 10 mg oral dose of 15 the compound of structural formula (I).

The present invention further relates to the use of such capsules for treatment of sexual dysfunction, e.g., male erectile dysfunction and 20 female arousal disorder.

#### DETAILED DESCRIPTION OF THE INVENTION

For purposes of the invention disclosed 25 and claimed herein, the following terms and abbreviations have the following meanings.

The term "treatment" is defined to include preventing, lowering, stopping, or reversing the progression or severity of a condition or symptom 30 being treated. As such, the present invention includes both medical therapeutic and/or prophylactic administration, as appropriate.

- 5 -

The term "effective amount" is an amount of a pharmaceutical composition that is effective in treating the target condition or symptom. An effective amount of the compound of structural formula (I) to treat sexual dysfunction in a male is an amount sufficient to provide and sustain an erection capable of penetrating his partner. An effective amount of the compound of structural formula (I) to treat female sexual dysfunction, particularly female arousal disorder, is an amount sufficient to enhance the patient's ability to achieve or sustain an aroused state.

The term "free drug" refers to solid particles consisting essentially of the compound of structural formula (I), as opposed to the compound intimately embedded in a polymeric coprecipitate.

The term "suspending agent" refers to a compound or composition that prevents or retards the settling of solid particles of the compound of structural formula (I) from a liquid suspension of the particles.

The term "suspension" refers to solid particles of the compound of structural formula (I) dispersed in a liquid carrier.

The term "solvate" refers one or more molecules of a solute associated with a molecule of a compound, such as the compound of structural formula (I) associated with a molecule of water or acetic acid.

The term "surfactant" refers to nonionic surfactants. Nonlimiting, representative surfactants include polysorbate 20, polyoxy 40 hydrogen-

- 6 -

ated castor oil, and tocophersolan (d- $\alpha$ -tocopheryl polyethylene glycol 1000 succinate).

The term "solid oral dosage form" is used in a general sense to refer to pharmaceutical products administered orally. General oral dosage forms are recognized by those skilled in the art to include such forms as tablets and capsules, for example.

The nomenclature describing the particle size is commonly referred to herein as the "d90." A d90 of 40 means that at least 90% of the particles have a particle size less than 40 microns.

As previously stated, the present invention provides pharmaceutical formulations containing the compound of structural formula (I), as disclosed in Daugan U.S. Patent No. 5,859,006, and pharmaceutically acceptable salts and solvates thereof. A preferred solvent suitable to prepare such a compound includes acetic acid.

Applicants have found that dosage uniformity, stability, and bioavailability are enhanced by formulating (6R-trans)-6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methylpyrazino-[1',2':1,6]pyrido[3,4-b]indole-1,4-dione (referred to herein as Compound A) with a pharmaceutically acceptable solvent, and incorporating the resulting solution or suspension into a soft shell to provide a capsule of the present invention.

The total amount of active compound in the pharmaceutical formulation is about 1% to about 45%, preferably about 2% to about 20%, by weight of the formulation. The active compound used in the present invention can be made according to estab-

- 7 -

lished procedures, such as those detailed in Daugan U.S. Patent No. 5,859,006, incorporated herein by reference.

For capsules containing a dispersion of Compound A, the particle size of the active compound has been found to enhance the bioavailability and handling of the present formulations. Thus, the particle size of the compound of structural formula (I) prior to formulation is controlled by milling the raw drug (as a crystal, amorphous precipitate, or mixture thereof) such that at least 90% of the particles have a particle size of less than about 40 microns ( $d_{90}=40$ ), and preferably less than about 30 microns. More preferably, at least 90% of the particles have a particle size of less than about 25 microns, still more preferably, less than about 15 microns, and most preferably, less than about 10 microns.

Methods for determining the size of particles are well known in the art. The following nonlimiting method, disclosed in U.S. Patent No. 4,605,517, incorporated herein by reference, can be employed. In particular, the laser scattering particle size distribution analysis is effected on a small sample of the reduced material which is suspended in approximately 180 ml of dispersant solution. The sample is added to the dispersant until an acceptable level of laser light obscuration is achieved, at which point the particle size distribution is measured. Prior to the sample suspension, the dispersant solution is prepared by preparing a solution of 0.1% SPAN 80 (sorbitan oleate) in cyclohexane which is presaturated with



- 8 -

the compound. The dispersant solution is filtered through a 0.2 micron microporous membrane filter to provide the necessary particle-free suspending dispersant. Triplicate measurements are effected as a minimum (a) to produce more reliable measurements, and (b) to check the equivalent sampling of the suspended material. The results are automatically recorded and displayed graphically to give a cumulative % undersize vs. diameter, and a frequency percentage vs. diameter for the sample. From this data, the median equivalent spherical volume diameter value and d90 are derived (90% undersize value) together with the standard deviation of the distribution calculated as above.

A formulation of the present invention is a suspension or solution filled in soft capsules, such as gelatin capsules. Such capsules often are referred to as "soft elastic capsules" (SEC) or "softgels" by persons skilled in the art. Capsule formulations are especially preferred for an active compound having a low solubility, such as the compound of structural formula (I). For example, Compound A has a water solubility of about 2  $\mu$ g (micrograms) per milliliter of water at 25°C. Compounds having a low solubility have demonstrated a low and inconsistent bioavailability. Soft gelatin capsules containing a solution or suspension of the low solubility compound of structural formula (I) have overcome problems associated with drug bioavailability, while providing an oral dosage form preferred by patients.

The specific dose of Compound A administered according to the present invention is

- 9 -

determined by the particular circumstances surrounding the case including, for example, the dosage form, the route of administration, the state of being of the patient, and the pathological condition being treated. A typical daily dose is about 1 to about 20 mg/day of the compound of structural formula (I). Preferred daily doses generally are about 2 to about 15 mg/day, and particularly about 5 mg or about 10 mg doses, administered once per day. Multiple doses can be taken to achieve a total dose of up to about 20 mg/day of the compound of structural formula (I). The selection of a particular dose is decided by the attending physician.

The present invention is particularly directed to an improved solid oral dosage form for a PDE5 inhibitor, in particular for a PDE5 inhibitor having a low water solubility, such as Compound A. The improved dosage form can be used to treat sexual dysfunction, particularly male erectile dysfunction and female arousal disorder.

The improved solid oral dosage form is soft capsules, such as soft gelatin capsules, comprising a shell that encapsulates a solution or suspension of Compound A. In accordance with the present invention, the soft capsules are a solid dosage form in which a drug is encapsulated in a soft container or shell comprising a suitable form of gelatin. Gelatin possesses unique properties which make gelatin the primary material for the manufacture of soft capsule shells over other capsule shell materials, such as methylcellulose and calcium alginate.

- 10 -

Soft capsules provide advantages over other solid dosage forms, such as tablets. For example, many patients prefer capsules because capsules are easier to swallow. Thus, capsule forms of a drug often are made available in addition to tablet forms.

A soft capsule, or softgel, has a soft, globular, gelatin shell, typically plasticized by the addition of glycerin, sorbitol, or a similar polyol. The shell is filled with a suspension or solution of the compound of structural formula (I). The size and shape of the gelatin shell can vary widely. The shell, therefore, can be spherical, oval, oblong, or tube shaped, for example. The size of the capsule is related to the dose level of the drug encapsulated by the shell, and to the solubility and dispersability of the drug in the pharmaceutically acceptable solvent or carrier for the drug.

A soft capsule for an oral dosage of a drug typically is prepared such that a seam in the gelatin shell, or the shell itself, ruptures to release the drug solution or suspension within five to ten minutes after ingestion. Manufacture of the soft gelatin shell to encapsulate the drug suspension or solution is performed in accordance with methods well known in the art.

Compound A has an extremely low solubility in water of about 2  $\mu\text{g/ml}$ , and has demonstrated a low and inconsistent bioavailability. Although Compound A is relatively insoluble in water, it is readily soluble in a variety of organic solvents, such as dimethylformamide and dimethyl sulfoxide.

- 11 -

However, such solvents are not pharmaceutically acceptable. The present invention is directed to a formulation for filling a soft gelatin shell, and thereby providing a soft capsule that is both physically and chemically stable, and allows the manufacture of capsules having the smallest possible size. As described hereafter, a solution formulation and a suspension formulation were prepared to provide a soft capsule having a gelatin shell encapsulating an effective dose of Compound A.

The following formulation examples are illustrative only and are not intended to limit the scope of the present invention.

#### EXAMPLE 1

##### Capsules Containing a Solution Formulation

The solubility of Compound A was determined in various pharmaceutically acceptable solvents. These solvents included hydrophilic solvents, such as polyethylene glycol 400 (PEG 400), propylene glycol, and glycofurool, and lipophilic solvents, such as triethyl citrate, propylene glycol mono- and dilaurate, and medium chain ( $C_8$  and  $C_{10}$ ) mono-, di-, and triglycerides. The solubility studies showed that Compound A has an extremely low solubility in lipophilic solvents.

The solubility of Compound A in hydrophilic solvents was determined by dissolving increasing amounts of Compound A, i.e., 2% to 5% by weight, in a pharmaceutically acceptable solvent, e.g., PEG 400, alone or in the presence of povidone (i.e., a medium molecular weight polyvinylpyrrolidone (PVP))

- 12 -

at 60±5°C. The solutions then were allowed to cool to room temperature (RT). A portion of each solution was mixed with water (8 mg water per 100 mg solution) to mimic the water migration and retention processes occurring in a soft capsule. The solutions (with and without water) were stored at RT (room temperature) and at 4°C for physical stability evaluation. In this evaluation, the solutions were observed under a microscope at regular intervals for the presence of drug crystals.

The physical stability evaluation showed that compositions containing 2% to about 2.8% by weight of Compound A, 5% by weight of propylene glycol, and the remainder PEG 400 were stable in that no crystals of Compound A were observed after 120 days of storage. The solubility study of Compound A in PEG 400 indicated that a solution formulation of Compound A was physically stable with respect to drug crystallization at room temperature and at 4°C at about 2.8% or lower drug concentrations. Accordingly, 25 mg of Compound A can be encapsulated in a gelatin shell at a 900 mg or greater fill weight.

A batch of soft capsules then was manufactured by encapsulating 900 mg of a PEG 400 solution containing 25 mg of Compound A in a gelatin shell. The capsules were manufactured using a standard gelatin formulation as the shell, with sorbitol and glycerin as the plasticizers and titanium dioxide as the shell opacifier. The encapsulation process was performed using an oblong, shallow body die, having a thickness of 0.22 inch, for the shell. This shell thickness provided a fast

- 13 -

release of the solution formulation from the capsules, which results in a rapid absorption by a human body, and an expected rapid onset of action. The solution formulation and physical stability are summarized in the following table.

Formulation			
Ingredients		mg/capsule	
Filling Solution:			
Compound A		25	
PEG 400 NF, LA <sup>11</sup>		830	
Propylene glycol, USP		45	
Fill Weight, mg		900	
Fill moisture (%) Day 1		6.86	6.76
Day 2		8.8	9.8
Hardness (Newtons)			
Size/Shape		Oblong-Shallow body die	
Capsule Shell Ingredients:			
Gelatin, Lime bone			
Glycerin			
Sorbitol			
Water, purified			
Titanium dioxide			
Shell Color		Opaque White	
Physical Stability:			
Days		120	
4°C		No Crystals	
RT		No Crystals	

<sup>11</sup> polyethylene glycol 400, low aldehyde

The physical stability of the capsules of Example 1 was evaluated at room temperature and at 4°C. The chemical stability of the capsules also was evaluated at 25°C and 60% relative humidity

- 14 -

(real time conditions) and at 40°C and 75% relative humidity (accelerated stability conditions). The dissolution profiles were measured using the USP Paddle method at 75 rpm in 1000 ml of 0.5% sodium lauryl sulfate solution at 37°C±0.5°C. The dissolution profiles and chemical stability data are summarized in the following tables.

10

Dissolution Profile Results				
Rupture Time	Average Dissolution (%) n=6			
min:sec	10 min.	20 min.	30 min.	60 min.
1:17-8:08	97	99	99	99

15

n=number tested

20

Chemical Stability Results			
Time & Conditions	Assay, % (n=2)	Related Substances, % (n=2)	Chiral Impurities, % (n=2)
Initial 40°C/75% RH	98.6	0.15	N/A
30 days 40°C/75% RH	99.1	0.15	N/A
60 days 40°C/75% RH	98.7	0.40	0.30
90 days 40°C/75% RH	98.6	0.60	0.45
90 days 25°C/60% RH	99.5	0.40	0.10

25

30

35

The capsules of Example 1 showed that capsules containing 25 mg of Compound A were physically stable with respect to crystallization at room temperature and 4°C for more than four months.

40

- 15 -

Dissolution profiles, in 0.5% sodium lauryl sulfate solution, showed more than 80% of Compound A was dissolved within first 10 minutes, and dissolution was complete within the first 20 minutes.

5           In addition, no significant chemical degradation of Compound A was observed after storage of the capsules for three months under accelerated stability conditions. The total of related substances was as low as 0.6%, and the total chiral  
10       impurity was as low as 0.45%, in capsules stored under accelerated stability conditions for more than three months.

#### EXAMPLE 2

##### 15       Capsules Containing a Suspension Formulation

Suspension formulations were investigated using a hydrophilic carrier (i.e., PEG 400) and using a lipophilic carrier (i.e., CAPMUL<sup>®</sup> MCM).  
20       CAPMUL<sup>®</sup> MCM is a mixture of medium chain (C<sub>8</sub>-C<sub>10</sub>) monoglycerides, available commercially from Capital City Products Co., Columbus, Ohio.

The suspensions were prepared by dispersing Compound A in a mixture of (a) a suspending  
25       agent, GELUCIRE<sup>®</sup> 44/14, and (b) either PEG 400 or CAPMUL<sup>®</sup> MCM. GELUCIRE<sup>®</sup> 44/14 is a blend of a saturated polyglycolyzed glycerides, available commercially from Gattefosse SA, Saint Priest, France.  
30       GELUCIRE<sup>®</sup> 44/14 and CAPMUL<sup>®</sup> MCM, separately, were premelted to about 60°C, then mixed to provide a suspension carrier. The carrier was allowed to cool to 40°C, then Compound A was dispersed in the carrier. Different ratios of GELUCIRE<sup>®</sup> 44/14 to



- 16 -

CAPMUL<sup>®</sup> MCM or PEG 400 were studied to provide a suspension formulation that was easy to encapsulate below 35°C and exhibited good dispersion (suspension) properties. The effect of incorporating a surfactant into the carrier, such as TWEEN<sup>®</sup> 20 (polysorbate 20), CREMOPHOR<sup>®</sup> RH 40 (PEG 40 hydrogenated castor oil), and vitamin E TPGS<sup>®</sup> (tocophersolan), also was studied.

The suspensions were stored at room temperature, and evaluated by observation under a microscope at regular intervals for drug crystal growth in the suspension base. The suspensions were evaluated for physical stability in PEG 400 and CAPMUL<sup>®</sup> MCM over a concentration range of Compound A of 6.25% to 40%.

The studies on the suspension formulation in PEG 400 indicated that the formulation was physically stable with respect to Compound A sedimentation at room temperature. Suspension formulations containing CAPMUL<sup>®</sup> MCM and GELUCIRE<sup>®</sup> 44/14 as a carrier also demonstrated physical stability, and also exhibited better flow properties and dispersion in water than PEG 400-based formulations. In particular, compositions containing 6.25% Compound A; 5% propylene glycol; CAPMUL<sup>®</sup> MCM from 11.39% to 56.875%; and GELUCIRE<sup>®</sup> 44/14 from 31.875% to 74.67% were free flowing and showed a fair dispersion in water. The presence of a surfactant in the carrier had little to no effect on the formulations.

A formulation containing 6.25% Compound A, 5% propylene glycol, 44.375% CAPMUL<sup>®</sup> MCM, and 44.375% GELUCIRE<sup>®</sup> 44/14 was evaluated further.

- 17 -

Using this formulation, 25 mg of Compound A was encapsulated at a 400 mg capsule fill weight.

5 A batch of soft capsules was manufactured by incorporating 400 mg of the above suspension formulation containing 25 mg Compound A in a standard soft gelatin shell having sorbitol and glycerin as shell plasticizers and titanium dioxide as the shell opacifier. The encapsulation process was performed using a oval shallow body die of 0.22  
10 inch thickness.

Capsules containing the above suspension, and the physical and chemical stability of the capsules, are summarized in the following tables.

- 18 -

Formulation			
Ingredients		mg/capsules	
Filling Suspension:			
Compound A	25.0		
5CAPMUL <sup>®</sup> MCM	177.5		
GELUCIRE <sup>®</sup> 44/14	177.5		
Propylene glycol, USP	20.0		
Fill Weight, mg	400		
10Fill Moisture (%) Day 1 Day 2	3.17		2.17
Hardness (Newtons)	5.0		5.9
Size/Shape	Oval--Shallow body die		
Capsule Shell Ingredients:			
Gelatin, Lime bone			
Glycerin			
15Sorbitol, special			
Water, purified			
Titanium dioxide			
Shell Color	Opaque White		
Physical Stability:			
20Days	120		
4°C	No sedimentation		
RT	No sedimentation		
40°C/75% RH	Sedimentation		

The physical and chemical stability of the capsules of Example 2 were evaluated using the criteria described in Example 1.

- 19 -

Dissolution Profile Results				
Rupture Time	Average Dissolution (%) (n=6)			
min:sec	10 min.	20 min.	30 min.	60 min.
0:40-1.39	63	82	90	96

Chemical Stability Results			
Time & Conditions	Assay, % (n=2)	Related Substances, % (n=2)	Chiral Impurities, % (n=2)
Initial 40°C/75% RH	96.5	0.15	N/A
30 days 40°C/75% RH	97.4	0.05	N/A
60 days 40°C/75% RH	97.1	0.10	N/A

The capsules of Example 2 demonstrated that soft capsules containing a suspension formulation incorporating 25 mg of Compound A were physically stable with respect to sediment formation at RT and 4°C for more than four months. Slight settling of Compound A as a sediment was observed in capsules stored under accelerated stability conditions. In dissolution profiles, the suspension-filled capsules of Example 2 exhibited a total dissolution of Compound A in the dissolution medium beyond a 30-minute time period.

No significant degradation of Compound A was observed after two months storage when the capsules were stored under accelerated stability conditions. The total of related substances was as

- 20 -

low as 0.1% in capsules stored under accelerated stability condition for two months.

**EXAMPLE 3****5      Capsules Containing a Solution Formulation**

The following is a soft gelatin capsule containing a 10 mg dose of a solution of Compound A.

10	<b>Ingredients</b>	<b>mg/capsules</b>
	<b>Filling Solution:</b>	
	Compound A	10
	PEG 400 NF, LA	465
	Propylene glycol, USP	25
15	Fill Weight, mg	500
	Fill moisture (%) Day 1	6.60
	Hardness (Newtons)	7.7
	Size/Shape	Oval--Shallow body die
	<b>Capsule Shell Ingredients:</b>	
20	Gelatin, Lime bone	
	Glycerin	
	Sorbitol, special	
	Water, purified	
	Titanium dioxide	
25	Shell Color	Opaque White
	<b>Physical Stability:</b>	
	Days	60
	4°C	No Crystals
30	RT	No Crystals

- 21 -

The capsules of Example 3 exhibited an excellent dissolution profile and excellent chemical stability as demonstrated in the following tables.

5

Dissolution Results				
Rupture Time	Average Dissolution (%) n=6			
min:sec	10 min.	20 min.	30 min.	60 min.
3:40-5:39	95	98	99	101

10

15

Chemical Stability Results			
Time & Conditions	Assay, % (n=2)	Related Substances, % (n=2)	Chiral Impurities, % (n=2)
Initial 40°C/75% RH	99.2	0.30	-0-
30 days 40°C/75% RH	99.0	0.45	0.2
60 days 40°C/75% RH	98.5	0.55	0.45

20

25

30

In addition to improved *in vivo* absorption, other important physical properties are dissolution and stability. The present soft capsules provide a fast-dissolving oral dose form having excellent stability.

35

The principles, preferred embodiments, and modes of operation of the present invention have been described in the foregoing specification. The invention that is intended to be protected herein, however, is not construed to be limited to the particular forms disclosed, because they are to be regarded as illustrative rather than restrictive.


- 22 -

Variations and changes may be made by those skilled in the art without departing from the spirit of the invention.

- 23 -

## WHAT IS CLAIMED IS:

1. A soft capsule comprising:
  - (a) a shell comprising gelatin, wherein said shell encapsulates
  - (b) a pharmaceutical formulation comprising an active compound having the structural formula



and a pharmaceutically acceptable carrier.

2. The capsules of claim 1 wherein the pharmaceutical formulation is a solution of the active compound in a pharmaceutically acceptable carrier.

3. The capsules of claim 1 wherein the pharmaceutical formulation is a suspension containing solid particles of the active compound in a pharmaceutically acceptable carrier.



- 24 -

4. The capsules of claim 3 wherein the active compound is present as a free drug.

5. The capsules of claim 1 wherein the active compound is present in an amount of about 1% to about 45% by weight of the pharmaceutical formulation.

6. The capsules of claim 1 wherein the pharmaceutically acceptable carrier comprises a pharmaceutically acceptable solvent.

7. The capsules of claim 6 wherein the pharmaceutically acceptable solvent is selected from the group consisting of polyethylene glycol 400, propylene glycol, glycofurol, and mixtures thereof.

8. The capsules of claim 6 wherein the pharmaceutically acceptable carrier further comprises a polyvinylpyrrolidone.

9. The capsules of claim 2 wherein the pharmaceutical formulation comprises about 2% to about 2.8% by weight of the active compound, about 3% to about 8% by weight propylene glycol, and about 90% to about 95% by weight polyethylene glycol 400.

10. The capsules of claim 3 wherein the pharmaceutically acceptable carrier comprises a pharmaceutically acceptable solvent and a suspending agent.

- 25 -

11. The capsules of claim 10 wherein the pharmaceutically acceptable solvent is selected from the group consisting of polyethylene glycol 400, propylene glycol, glycofurol, a C<sub>8</sub>-C<sub>10</sub> monoglyceride, and mixtures thereof.

12. The capsules of claim 10 wherein the suspending agent comprises a saturated polyglycolyzed glyceride.

13. The capsules of claim 10 wherein the suspending agent comprises a saturated polyglycolyzed glyceride and the solvent comprises C<sub>8</sub>-C<sub>10</sub> monoglycerides.

14. The capsules of claim 10 wherein the pharmaceutically acceptable carrier further comprises a surfactant.

15. The capsules of claim 3 wherein the pharmaceutical formulation comprises about 3% to about 8% by weight of the active compound, about 5% to about 8% by weight propylene glycol, about 10% to about 60% by weight of C<sub>8</sub>-C<sub>10</sub> monoglycerides, and about 30% to about 75% by weight of a polyglycolyzed glyceride.

16. The capsules of claim 1 wherein the active compound is present in an amount of about 1 to about 20 mg per capsule.

- 26 -

17. The capsules of claim 1 wherein the active compound is present in an amount of about 2 to about 20 mg per capsule.

18. The capsules of claim 1 wherein the active compound is present in an amount of about 5 to about 15 mg per capsule.

19. The capsules of claim 1 wherein the active compound is present in an amount of about 10 mg per capsule.

20. A method of treating sexual dysfunction in a patient in need thereof comprising administering to the patient a capsule of any of claims 1 to 19.

21. The invention as hereinabove described.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/11136

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/495 A61P15/10 A61K9/48

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 97 03675 A (GLAXO WELLCOME LAB SA ;DAUGAN ALAIN CLAUDE MARIE (FR)) 6 February 1997 (1997-02-06) cited in the application page 1, line 31 -page 2, line 8 page 3, line 24 - line 25 page 3, line 30 -page 4, line 16 page 5, line 15 - line 26; example 1 page 16, line 4 - line 9; claims 1,2,4-12; example 1</p> <p style="text-align: center;">--- -/-</p>	<p>1,3-6, 20,21</p>

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

30 August 2000

Date of mailing of the international search report

07/09/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Marttin, E

# INTERNATIONAL SEARCH REPORT

Inter. .onal Application No

PCT/US 00/11136

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 96 38131 A (GLAXO GROUP LTD ;BUTLER JAMES MATTHEW (GB))  5 December 1996 (1996-12-05)  cited in the application  page 4, line 15 - line 21  page 6, line 5 - line 11  page 7, line 33 -page 8, line 9  page 10, line 29 -page 11, line 3  page 14, line 13 -page 16, line 5  page 18, line 5 -page 19, line 51,2,5</p>	1,20,21
X	<p>WO 99 30697 A (WYLLIE MICHAEL GRANT ;PFIZER PROD INC (US))  24 June 1999 (1999-06-24)  page 3, line 24 -page 4, line 9  page 4, line 23 - line 29  page 5, line 29 -page 6, line 9  page 10, line 14 -page 12, line 12  page 17, line 17 - line 31</p>	1,6,20,21
A	<p>EP 0 649 651 A (SANDOZ AG ;SCHERER GMBH R P (DE)) 26 April 1995 (1995-04-26)  page 2, line 5 - line 24  page 3, line 42 - line 49  page 4, line 41 - line 48; claims 1,6-8; examples</p>	1-19

## INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 00 /1136

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claim 21 does not meet the requirements of Article 6 PCT in that the subject-matter for which protection is sought is not clearly defined. A lack of clarity (and/or conciseness) within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible. Consequently, the search has been carried out for those parts of the application which do appear to be clear (and/or concise), namely claim 21 insofar as a composition according to claims 1-20 was concerned.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/11136

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9703675 A	06-02-1997	AU 704955 B	13-05-1999
		AU 6419196 A	18-02-1997
		BR 9609758 A	26-01-1999
		CA 2226784 A	06-02-1997
		CN 1195290 A	07-10-1998
		CZ 9800033 A	13-05-1998
		EP 0839040 A	06-05-1998
		HU 9900065 A	28-05-1999
		JP 11509221 T	17-08-1999
		NO 980153 A	10-03-1998
		PL 324495 A	25-05-1998
		SK 3998 A	08-07-1998
WO 9638131 A	05-12-1996	AU 6002696 A	18-12-1996
		EP 0828479 A	18-03-1998
		US 5985326 A	16-11-1999
WO 9930697 A	24-06-1999	AU 9455898 A	05-07-1999
EP 0649651 A	26-04-1995	AU 690571 B	30-04-1998
		AU 7423794 A	13-04-1995
		AU 7511298 A	01-10-1998
		CA 2132933 A	29-03-1995
		CN 1108930 A	27-09-1995
		CZ 9402360 A	12-04-1995
		EP 1029538 A	23-08-2000
		FI 944452 A	29-03-1995
		FR 2710532 A	07-04-1995
		GB 2282586 A,B	12-04-1995
		GB 2317155 A,B	18-03-1998
		HU 70417 A	30-10-1995
		IT RM940613 A,B	28-03-1995
		JP 7149625 A	13-06-1995
		KR 200174 B	15-06-1999
		KR 202331 B	15-06-1999
		NO 943563 A	29-03-1995
		NZ 264536 A	25-09-1996
		PL 305188 A	03-04-1995
		RU 2140783 C	10-11-1999
		SG 46531 A	20-02-1998
		SK 115794 A	10-05-1995
		US 5985321 A	16-11-1999
		ZA 9407567 A	28-06-1996